21:54 , Dec 1, 2017 |  BC Week In Review  |  Company News

Arcturus, Synthetic Genomics partner for RNA-based vaccines

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) granted Synthetic Genomics Inc. (La Jolla, Calif.) exclusive, worldwide rights to its LUNAR lipid-mediated delivery technology to develop self-amplifying RNA-based vaccines and therapeutics for humans and animals based on Synthetic Genomics'...
21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
17:55 , Oct 6, 2017 |  BC Week In Review  |  Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...
04:30 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Metadoxine ER: Ph III MEASURE data

Top-line data from the double-blind, U.S. and Israeli Phase III MEASURE trial in 283 adult patients with ADHD showed that once-daily 1,400 mg oral metadoxine ER missed the primary endpoint of improving CAARS from baseline...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Metadoxine ER: Phase III hold

FDA placed a full clinical hold on metadoxine ER to treat ADHD and fragile X syndrome, which affects the double-blind, placebo-controlled, international Phase III MEASURE trial in about 750 ADHD patients. According to Alcobra, FDA...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 28, 2016 |  BC Extra  |  Clinical News

Alcobra's MDX on hold

Alcobra Ltd. (NASDAQ:ADHD) said FDA placed a clinical hold on the company's MDX metadoxine ER to treat ADHD and fragile X syndrome, including the Phase III MEASURE study in ADHD. According to Alcobra, FDA said...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Curbed enthusiasm

Following three years of investor exuberance manifested in gains of at least 115% in biotech indices, buysiders say a good 2016 would see biotech merely keeping pace with the broader markets. Nobody is calling an...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Financial News

Alcobra completes follow-on

Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel   Business: Neurology   Date completed: 2015-11-13   Type: Follow-on   Raised: $40.1 million   Shares: 6.2 million   Price: $6.50   Shares after offering: 27.4 million   Underwriters: Jefferies; Barclays Capital; Oppenheimer; Roth Capital Partners; Cantor...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Metadoxine ER regulatory update

FDA granted Fast Track designation to metadoxine ER from Alcobra to treat Fragile X syndrome. The extended-release formulation of metadoxine, a selective antagonist of the serotonin (5-HT2B) receptor, completed a Phase II trial for...